Get the Stockscreener App
14.09
0.03%
0.0047
After Hours:
14.28
0.1903
+1.35%
Apollomics Inc stock is traded at $14.09, with a volume of 1,302.
It is up +0.03% in the last 24 hours and up +6.08% over the past month.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
See More
Previous Close:
$14.09
Open:
$14.0897
24h Volume:
1,302
Relative Volume:
0.17
Market Cap:
$30.94M
Revenue:
$8.50M
Net Income/Loss:
$-10.94M
P/E Ratio:
-1.8613
EPS:
-7.57
Net Cash Flow:
$-28.76M
1W Performance:
-0.78%
1M Performance:
+6.08%
6M Performance:
-7.55%
1Y Performance:
+99.01%
1-Day Range:
$14.09
$14.09
1-Week Range:
$13.53
$15.41
52-Week Range:
$3.659
$42.12
Apollomics Inc Stock (APLM) Company Profile
Compare APLM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLM
Apollomics Inc
|
14.09 | 30.93M | 8.50M | -10.94M | -28.76M | -7.57 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apollomics Inc Stock (APLM) Latest News
Apollomics Warrants (APLMW) Hold at $0.01 After Modest Gain – Tight Trading Range PersistsCommunity Buy Alerts - Newser
APLM SEC FilingsAPOLLOMICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
APLMW Technical Analysis | Trend, Signals & Chart Patterns | APOLLOMICS INC-27 (NASDAQ:APLMW) - ChartMill
Apollomics Inc. (APLMW) Warrants Trade at $0.01 After Double-Digit DeclineSell Signal Alerts - Newser
Apollomics (APLM) director converts 500 RSUs into Class A shares - Stock Titan
How (APLM) Movements Inform Risk Allocation Models - Stock Traders Daily
Apollomics (APLMW) Stock Analysis Report | Financials & Insights - Benzinga España
Apollomics Inc. (APLM) files F-3/A to register 279,775 Class A shares - Stock Titan
Is Apollomics (APLM) Still a Buy After +10.29% Rally? 2026-05-15Investment Picks - newser.com
Apollomics (APLM) Climbs +0.54% — Resistance at $14.28 in Focus 2026-05-14Social Buy Zones - newser.com
TradingKey - TradingKey
What to expect when Apollomics (APLMW) reports earnings |AI Powered Stock Picks - Newser
Trading Systems Reacting to (APLM) Volatility - Stock Traders Daily
The labor dynamics in Apollomics (APLM) results |Inventory Turnover - newser.com
APLMW | Apollomics Inc. Warrant Insider Trading - Quiver Quantitative
Is Apollomics (APLMW) dividend sustainable? (Smart Money Exits) 2026-04-29Expert Verified Trades - newser.com
Apollomics (Nasdaq: APLM) slashes 2025 loss amid cost cuts and new vebreltinib deal revenue - Stock Titan
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress - marketscreener.com
How Apollomics Inc. (APLM) Affects Rotational Strategy Timing - Stock Traders Daily
Over 282 subjects enrolled as Apollomics targets 2027 U.S. filing - Stock Titan
APLM Apollomics highlights oncology pipeline progress and upcoming clinical trial milestones in its latest quarterly earnings report.Gamma Squeeze - Newser
APLM: Strategic restructuring and licensing revenue reduced losses, but liquidity and going concern risks persist - TradingView
Apollomics (NASDAQ: APLM) warns on going concern, defers vebreltinib NDA and writes down asset - Stock Titan
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
APLM Forecast — Price Target — Prediction for 2027 - TradingView
Apollomics Inc. Warrant (APLMW) - Minichart
Apollomics (APLM) Stock: Is It a Smart Investment (Slight Loss) 2026-04-18Crowd Entry Signals - Cổng thông tin điện tử tỉnh Lào Cai
Hong Jung Chen Net Worth (2026) - GuruFocus
Ya Chi Huang Net Worth (2026) - GuruFocus
Peter Kuan How Lin Net Worth (2026) - GuruFocus
Yi Kuei Chen Net Worth (2026) - GuruFocus
Chen Huan Jan Net Worth (2026) - GuruFocus
Hsien Shu Tsai Net Worth (2026) - GuruFocus
Apollomics (APLM) director details RSUs, options and warrants in Form 3/A - Stock Titan
Apollomics (APLM) CFO has shares withheld for RSU tax obligations - Stock Titan
(APLM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
[Form 3/A] Apollomics Inc. Amended Initial Statement of Beneficial Ownership - Stock Titan
Apollomics (APLM) director Jan Chen-Huan reports 1,000 RSUs and 1,000 shares - Stock Titan
Apollomics (APLM) CFO details 20,000 RSUs and 15,900 shares in Form 3/A - Stock Titan
Apollomics (ticker: APLM) CEO details direct and indirect share stakes - Stock Titan
Apollomics (APLM) director discloses 1,000 restricted stock units award - Stock Titan
Apollomics (APLM) COO details RSU grants and Maxpro warrant stakes - Stock Titan
Apollomics (APLM) director Huang Ya-Chi details RSU vesting and share holdings - Stock Titan
Tech Rally: Does Apollomics Inc Equity Warrant have pricing power2026 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Market Outlook: Is Apollomics Inc in a consolidation phase2026 Bull vs Bear & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Bear Alert: Can Apollomics Inc stock outperform in a bear marketWeekly Stock Analysis & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Bond Watch: Can Apollomics Inc Equity Warrant expand its profit marginsEarnings Miss & Smart Swing Trading Techniques - baoquankhu1.vn
Aug Wrap: Will Apollomics Inc Equity Warrant outperform the market in YEARJobs Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Risk Off: Is Apollomics Inc attractive at current valuation2026 Analyst Calls & Long-Term Capital Growth Ideas - baoquankhu1.vn
What happens to Apollomics (APLM) Stock after earnings | Price at $15.10, Up 1.68%Debt Free Companies - Newser
Apollomics, Inc. (APLM) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Apollomics Inc Stock (APLM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):